Eupraxia Pharmaceuticals(TSE:EPRX)
CA$11.65+0.54 (+4.86%)
TSE:EPRX
Eupraxia Pharmaceuticals financials statements
CA$11.65
At close:+0.54 (+4.86%)
Want to see TSE:EPRX full AI Analyst Report?
Eupraxia Pharmaceuticals (EPRX) Income Statement
82 Followers
Eupraxia Pharmaceuticals Income Statement
Last quarter (Q3 2026), Eupraxia Pharmaceuticals's total revenue was C$0.00. In Q3, Eupraxia Pharmaceuticals's net income was C$-15.38M. See Eupraxia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| C$ 0.00 | C$ 0.00 | C$ 0.00 | C$ 0.00 | C$ 0.00 | |
| C$ -241.88K | C$ -163.47K | C$ -158.05K | C$ -193.27K | C$ -111.53K | |
| C$ 38.86M | C$ 25.54M | C$ 28.37M | C$ 23.38M | C$ 18.38M | |
| Depreciation and Amortization | C$ 241.88K | C$ 171.72K | C$ 117.41K | C$ 190.42K | C$ 111.53K |
| C$ -38.86M | C$ -23.42M | C$ -28.20M | C$ -22.14M | C$ -21.96M | |
| C$ -39.11M | C$ -25.71M | C$ -28.53M | C$ -23.58M | C$ -18.47M | |
| ― | C$ 1.20M | C$ -1.08M | C$ -341.08K | C$ -4.90M | |
| C$ -39.26M | C$ -24.51M | C$ -28.93M | C$ -23.92M | C$ -23.37M | |
| C$ -39.25M | C$ -24.28M | C$ -28.15M | C$ -23.26M | C$ -22.99M | |
| Per Share Metrics | |||||
| Basic EPS | C$ -1.05 | C$ -0.72 | C$ -1.19 | C$ -1.21 | C$ -1.61 |
| Diluted EPS | C$ -1.05 | C$ -0.72 | C$ -1.19 | C$ -1.21 | C$ -1.61 |
| Weighted Average Shares Outstanding | 39.96M | 33.93M | 24.15M | 19.29M | 14.24M |
| Weighted Average Shares Outstanding (Diluted) | 39.96M | 33.93M | 24.15M | 19.29M | 14.24M |
Currency in CAD

